康泰生物(300601.SZ)與阿斯利康簽署新冠疫苗獨家授權《許可協議》
格隆匯8月21日丨康泰生物(300601.SZ)公佈,公司與阿斯利康簽署了《約束性交易條款清單》,通過技術轉讓積極推進阿斯利康與牛津大學合作的腺病毒載體新冠疫苗AZD1222在中國內地市場的研發、生產、供應和商業化。
近日,雙方就該次合作的所有條款和條件達成一致意見,並簽署了《許可協議》,對雙方簽署的《約束性交易條款清單》進行了詳細規定。
公司擁有在中國內地開發許可產品的唯一權利。中國內地藥品上市持有人(MAH)均以公司的名義遞交併由公司擁有,公司應盡最大努力完成許可產品的開發,取得註冊批准,並全權負責許可產品的商業化。
根據《許可協議》,公司確保在2020年底前擁有至少每年生產1億劑許可產品的產能,在2021年底前擁有至少每年生產2億劑許可產品的產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.